Company Overview and News

 
Hot or Not? Probably the Latter for This IPO - Bloomberg Gadfly

2017-11-28 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Hong Kong shares shrug off robust China industrial profits

2017-11-27 thehindubusinessline
Hong Kong shares closed lower on Monday, as investors largely shrugged off data showing profits at China's industrial firms continued to grow at a robust pace last month despite a slight cooling from a sizzling September.
Upvote Downvote

 
Hang Seng ends below 30,000 points

2017-11-23 thehindubusinessline
Hong Kong stocks ended on Thursday sharply lower, with the benchmark Hang Seng falling back below the 30,000 point mark after the previous session's breakthrough, as a tumble in mainland stocks soured the sentiment.
Upvote Downvote

 
Chinese facial recognition start-up eyes global opportunities beyond public security

2017-11-22 scmp
Investment in Chinese artificial intelligence firms reached US$2.76 billion last year as Beijing looks to transform the nation into an AI innovation centre by 2030
Upvote Downvote

 
This start-up can identify you by your voice in a matter of seconds

2017-11-21 scmp
Voiceprint recognition is another area under artificial intelligence that China has pledged to build into a US$150 billion industry over the next few years
Upvote Downvote

1
Chinese AI Pioneer YITU announces plan to establish R&D Hub in Singapore to accelerate AI development in the nation and Asia market

2017-11-14 marketwired
SHANGHAI, CHINA--(Marketwired - Nov 14, 2017) - YITU Technology, a Chinese pioneer in artificial intelligence (AI), announced its plans to set up a Research & Development (R&D) Hub in Singapore, bolstering Singapore's AI applications in the area of security and finance. The discussion was held at a visit to YITU's Shanghai headquarters recently, represented by Singapore officials from the Ministry of Home Affairs (MHA) and Singapore's Economic Development Board (EDB), where they witnessed its award-winning facial recognition technologies.
Upvote Downvote

 
A skyrocketing tech firm set out to change the world. Its failure has changed China

2017-11-14 cnbc
Jia Yueting, the 44-year-old founder of Chinese tech company LeEco, once envisioned building a Chinese empire that would rival U.S. tech giants Netflix, Tesla and Apple all together.
Upvote Downvote

 
ICBC launches robo-adviser service for wealth-management products

2017-11-14 scmp
The nation’s largest bank by assets is first of China’s ‘big four’ lenders to offer automated advice and product service
Upvote Downvote

 
China Eases Limits on Foreign Stakes in Financial Firms - The New York Times

2017-11-13 nytimes
BEIJING — Hours after President Trump left China with a warning about its trade practices, Beijing threw him — and Wall Street — a bone.
Upvote Downvote

 
China opening its banks is great, if you like bad debt

2017-11-11 thestar.com.my
In a surprise move, and timed with US President Donald Trump’s state visit, China said it would scrap foreign ownership limits for banks and asset management firms.
Upvote Downvote

 
Bad-Debt Experts, China's Calling - Bloomberg Gadfly

2017-11-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Jupai - A Value Play in a High Growing Industry

2017-11-10 accesswire
NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Stone Street Group LLC ("Stone Street") publishes research reports on publicly-traded companies. Stone Street has been retained by the company discussed in this report (the "Company") to provide ongoing digital investor relations services, including the creation and dissemination of this report. All research published by Stone Street is based on public information, or on information from the Company that the Company is required to promptly make public.
Upvote Downvote

1
PBOC Moves to Steady Money Supply After Sovereign Bond Tumble - Bloomberg

2017-11-03 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
China early data show investors more confident than real economy

2017-10-30 themalaymailonline
A clerk arranges bundles of 100 Chinese yuan banknotes at a branch of China Merchants Bank in Hefei, Anhui province March 17, 2014. — Reuters picBEIJING, Oct 30 — The earliest gauges of China’s economic pulse for October suggest that sentiment among financial-market participants is more positive than that in the real economy.
Upvote Downvote

 
Xi's Neighborhood Watch - Bloomberg

2017-10-26 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...